Successful completion of the dose escalation study in patients with bladder cancer

By January 17, 2022 February 8th, 2022 No Comments

MON, JAN 17, 2022 12:15 CET

Hamlet Pharma has previously reported the successful completion of a Phase I/II study using a 1.7 mM dose of Alpha1H. We are now excited to report the successful completion of the dose escalation extension of the Phase I/II trial, demonstrating more potent effects of Alpha1H for key study parameters. The results are very encouraging for our continued work towards Phase III trials.

The tumors were more strongly affected by Alpha1H at higher doses than in patients treated with the lower dose, as shown by more extensive shedding of tumor cells and tumor fragments into patient urine. As shown earlier, significant cell shedding or apoptosis did not occur in the placebo group, confirming the treatment effect.

Tissue analysis detected tumor fragmentation and shedding of tumor fragments from the remaining tumor, with large affected areas. In addition to the changes in the tumors, a pronounced apoptotic response was detected in cells and tumor fragments shed by the treated patients, confirming that Alpha1H accelerates cell death in the tumor. Apoptosis is a beneficial, non-toxic form of cell death, and therapies inducing apoptosis in growing tumors are highly desirable to limit the side effects of cancer therapy.

Furthermore, the tumor fragments in urine were shown to contain large amounts of Alpha1H, confirming the efficiency with which the higher doses of Alpha1H reach tumor tissue. The results suggest that the uptake of Alpha1H by tumor cells is a direct trigger of apoptosis, tumor fragmentation and release of the affected tumor fragments into the urine.

Dose-finding studies are essential to understand the potential of new drugs and define the optimal therapeutic window. The dose-dependent increase in therapeutic efficacy further emphasizes the potential of Alpha1-oleate for use as a drug in bladder cancer.

“’The dose-finding studies are essential for the continued development of Alpha1H for Phase III trials and for the dialogue with authorities like the FDA,” says Catharina Svanborg, founder and chairman of the board of Hamlet Pharma Ltd. 

“We are delighted to have reached this point in our development towards Phase III trials” says Mats Persson, CEO of Hamlet Pharma Ltd.

This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-01-2022 12:15 CET.

For more information, please contact

 Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49

 Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57 

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.

This project is funded from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954360.

Hamlet Pharma

Author Hamlet Pharma

More posts by Hamlet Pharma

Hamlet Pharma AB

Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00